Centessa Pharmaceuticals plc (CNTA)

Market Cap	2.21B
Revenue (ttm)	6.85M
Net Income (ttm)	-161.27M
Shares Out	131.85M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	619,771
Open	16.97
Previous Close	16.83
Day's Range	16.46 - 17.34
52-Week Range	5.58 - 18.74
Beta	1.48
Analysts	Strong Buy
Price Target	23.71 (+41.64%)
Earnings Date	Nov 12, 2024

About CNTA

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 28, 2021
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: CNTA
• Website: https://www.centessa.com

Analyst Forecast

According to 7 analysts, the average rating for CNTA stock is "Strong Buy." The 12-month stock price forecast is $23.71, which is an increase of 41.64% from the latest price.

Price Target

$23.71

(41.64% upside)

Analyst Consensus: Strong Buy